ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of $0.13, $0.05 better than the analyst estimate of $0.08. Revenue for the quarter came in at $107.2 million versus the consensus estimate of $86.44 million.

GUIDANCE:

ADMA Biologics sees FY2024 revenue of $400-445 million, versus the consensus of $357.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.